Xtant Medical (XTNT) Projected to Post Earnings on Thursday

Xtant Medical (NYSEAMERICAN:XTNT) is anticipated to release its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect Xtant Medical to post earnings of ($0.0049) per share and revenue of $30.75 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 13, 2026 at 5:00 PM ET.

Xtant Medical Stock Performance

Shares of NYSEAMERICAN:XTNT opened at $0.57 on Tuesday. The company’s 50 day simple moving average is $0.65 and its 200 day simple moving average is $0.68. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.21 and a quick ratio of 1.06. Xtant Medical has a 1 year low of $0.34 and a 1 year high of $0.95. The stock has a market capitalization of $80.00 million, a price-to-earnings ratio of 57.20 and a beta of -0.30.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of XTNT. Jane Street Group LLC bought a new stake in shares of Xtant Medical in the 2nd quarter worth approximately $26,000. Wiregrass Investment Management LLC purchased a new stake in Xtant Medical in the fourth quarter worth $81,000. Mink Brook Asset Management LLC raised its stake in shares of Xtant Medical by 125.8% in the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after buying an additional 60,997 shares during the period. Renaissance Technologies LLC lifted its position in shares of Xtant Medical by 28.8% during the 4th quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock valued at $721,000 after buying an additional 205,945 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Xtant Medical by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock valued at $1,529,000 after buying an additional 104,159 shares during the last quarter. Hedge funds and other institutional investors own 69.33% of the company’s stock.

Wall Street Analyst Weigh In

Separately, BTIG Research lowered their target price on Xtant Medical from $2.00 to $1.50 and set a “buy” rating for the company in a report on Tuesday, November 11th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $1.50.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.